Marluce Bibbo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marluce Bibbo has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Albert J. Kovatich
21 shared publicationsAmy R. Peck
21 shared publicationsChengbao Liu
21 shared publicationsCraig D. Shriver
21 shared publicationsEdith P. Mitchell
21 shared publicationsFransiscus E. Utama
21 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 4: Low PTHrP transcript levels are associated with poor clinical outcome in KM-plotter breast cancer dataset. Association with outcome for PTHrP transcript levels in all breast cancer breast cancer cases (N=3,951) using overall survival as endpoint and 10-year censoring from the KM-plotter datasets. Parameters used are: PTHLH Affy ID: 206300_s_at; All cases included with no restrictions except exclusion of biased arrays; Recurrence-Free survival; Auto select best cutoff; Invert Hazard ratio values below 1. Samples were dichotomized into high and low PTHrP mRNA expression based on the auto-selected cutoff value of 52 (range 1-13641) followed by Kaplan-Meier survival analysis.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 4: Low PTHrP transcript levels are associated with poor clinical outcome in KM-plotter breast cancer dataset. Association with outcome for PTHrP transcript levels in all breast cancer breast cancer cases (N=3,951) using overall survival as endpoint and 10-year censoring from the KM-plotter datasets. Parameters used are: PTHLH Affy ID: 206300_s_at; All cases included with no restrictions except exclusion of biased arrays; Recurrence-Free survival; Auto select best cutoff; Invert Hazard ratio values below 1. Samples were dichotomized into high and low PTHrP mRNA expression based on the auto-selected cutoff value of 52 (range 1-13641) followed by Kaplan-Meier survival analysis.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 1: Cytoplasmic PTHrP protein levels are reduced in breast cancer cells relative to normal breast epithelial cells. Quantification of cytoplasmic PTHrP protein levels in a progression array of normal, DCIS, primary invasive breast cancer (grades 1-3; IDC1-3), and lymph node (LN) metastases revealed that cytoplasmic PTHrP levels are lower in invasive breast cancer. *p<0.05; **p<0.02; ***p<001.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 1: Cytoplasmic PTHrP protein levels are reduced in breast cancer cells relative to normal breast epithelial cells. Quantification of cytoplasmic PTHrP protein levels in a progression array of normal, DCIS, primary invasive breast cancer (grades 1-3; IDC1-3), and lymph node (LN) metastases revealed that cytoplasmic PTHrP levels are lower in invasive breast cancer. *p<0.05; **p<0.02; ***p<001.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 3: Low PTHrP transcript levels in breast cancer are associated with poor overall survival in estrogen receptor-positive (ER+) breast cancer and in lymph node(LN)-negative breast cancer. Association with outcome for PTHrP transcript levels in breast cancer using overall survival as endpoint and 10-year censoring from the GOBO dataset. Samples were stratified into three quantiles based on PTHrP expression: PTHrP Low (log2 expression -4.97 to -0.558), PTHrP Intermediate (log2 expression -0.558 to 0.247) and PTHrP High (log2 expression 0.247 to 6.075) followed by Kaplan-Meier survival analysis of (A) LN-negative, (B) LN-positive, (C) ER-positive and (D) ER-negative tumor subgroups.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 3: Low PTHrP transcript levels in breast cancer are associated with poor overall survival in estrogen receptor-positive (ER+) breast cancer and in lymph node(LN)-negative breast cancer. Association with outcome for PTHrP transcript levels in breast cancer using overall survival as endpoint and 10-year censoring from the GOBO dataset. Samples were stratified into three quantiles based on PTHrP expression: PTHrP Low (log2 expression -4.97 to -0.558), PTHrP Intermediate (log2 expression -0.558 to 0.247) and PTHrP High (log2 expression 0.247 to 6.075) followed by Kaplan-Meier survival analysis of (A) LN-negative, (B) LN-positive, (C) ER-positive and (D) ER-negative tumor subgroups.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 5: Higher nuclear PTHrP protein levels are associated with lower grade and estrogen receptor-positive (ER+) breast cancer. Nuclear PTHrP protein levels are significantly higher in well-differentiated, grade 1 tumors compared to grade 3 tumors (A) and significantly higher in ER-positive (ER pos) than in ER-negative (ER neg) breast cancer (B). **p<0.02; ***p<001.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 5: Higher nuclear PTHrP protein levels are associated with lower grade and estrogen receptor-positive (ER+) breast cancer. Nuclear PTHrP protein levels are significantly higher in well-differentiated, grade 1 tumors compared to grade 3 tumors (A) and significantly higher in ER-positive (ER pos) than in ER-negative (ER neg) breast cancer (B). **p<0.02; ***p<001.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Clinical Characteristics of Outcome Cohorts 1 and 2.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Clinical Characteristics of Outcome Cohorts 1 and 2.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 6: Nuclear PTHrP and nuclear pY-Stat5 protein levels are strongly positively correlated independent of breast cancer subtype. Scatterplot of nuclear PTHrP protein levels against nuclear pY-Stat5 levels according to immunohistochemistry-based subtyping. Regression lines were fitted using robust MM-estimation illustrating strong positive correlations between nuclear PTHrP and nuclear pY-Stat5 in Luminal A (R=0.460), Luminal B (R=0.460), HER2-positive (R=0.690) and triple negative (R=0.630) human breast cancer tissues.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 6: Nuclear PTHrP and nuclear pY-Stat5 protein levels are strongly positively correlated independent of breast cancer subtype. Scatterplot of nuclear PTHrP protein levels against nuclear pY-Stat5 levels according to immunohistochemistry-based subtyping. Regression lines were fitted using robust MM-estimation illustrating strong positive correlations between nuclear PTHrP and nuclear pY-Stat5 in Luminal A (R=0.460), Luminal B (R=0.460), HER2-positive (R=0.690) and triple negative (R=0.630) human breast cancer tissues.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 7: Schematic representation of structure of wildtype Stat5a and Stat5b, dominant-negative Stat5 (DN-Stat5) and constitutively-active Stat5 (CA-Stat5) proteins.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 7: Schematic representation of structure of wildtype Stat5a and Stat5b, dominant-negative Stat5 (DN-Stat5) and constitutively-active Stat5 (CA-Stat5) proteins.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 2: Positive correlation between nuclear PTHrP and nuclear pY-Stat5 protein levels across progression series of breast cancer. Scatterplot of nuclear PTHrP and nuclear pY-Stat5 protein levels in normal breast epithelia, ductal carcinoma in situ (DCIS), primary invasive breast cancer (IDC), and lymph node (LN) metastases. A positive correlation between nuclear PTHrP and nuclear pY-Stat5 protein levels was observed (R=0.536, N=92, p<0.001).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 2: Positive correlation between nuclear PTHrP and nuclear pY-Stat5 protein levels across progression series of breast cancer. Scatterplot of nuclear PTHrP and nuclear pY-Stat5 protein levels in normal breast epithelia, ductal carcinoma in situ (DCIS), primary invasive breast cancer (IDC), and lymph node (LN) metastases. A positive correlation between nuclear PTHrP and nuclear pY-Stat5 protein levels was observed (R=0.536, N=92, p<0.001).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 4: Low PTHrP transcript levels are associated with poor clinical outcome in KM-plotter breast cancer dataset. Association with outcome for PTHrP transcript levels in all breast cancer breast cancer cases (N=3,951) using overall survival as endpoint and 10-year censoring from the KM-plotter datasets. Parameters used are: PTHLH Affy ID: 206300_s_at; All cases included with no restrictions except exclusion of biased arrays; Recurrence-Free survival; Auto select best cutoff; Invert Hazard ratio values below 1. Samples were dichotomized into high and low PTHrP mRNA expression based on the auto-selected cutoff value of 52 (range 1-13641) followed by Kaplan-Meier survival analysis.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Supplementary Figure 4: Low PTHrP transcript levels are associated with poor clinical outcome in KM-plotter breast cancer dataset. Association with outcome for PTHrP transcript levels in all breast cancer breast cancer cases (N=3,951) using overall survival as endpoint and 10-year censoring from the KM-plotter datasets. Parameters used are: PTHLH Affy ID: 206300_s_at; All cases included with no restrictions except exclusion of biased arrays; Recurrence-Free survival; Auto select best cutoff; Invert Hazard ratio values below 1. Samples were dichotomized into high and low PTHrP mRNA expression based on the auto-selected cutoff value of 52 (range 1-13641) followed by Kaplan-Meier survival analysis.